After a median follow up of 41.6 months, the median OS of all patients enrolled was 21.7 months, and the 3-year OS rate was 30.2 %. There was no difference in survival between the two arms, with median OS time of 23.2 months in the observation arm and 21.2 months in the docetaxel arm (p=0.883) and 3-year OS rates of 26.1% and 27.1% respectively. There was also no difference in progression free survival between the two arms (p=0.960).
© J Clin Oncol 2008
Updated survival and outcome results, reported by Jalal et alr identified similar efficacy outcomes (OS and PFS) but higher rates of hospitalisation, grade 3/4 toxicities and treatment discontinuation in the elderly (>70 years) subpopulation analysis of this study.